Psychosomatic Medicine Faster Service from Outside North America
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rabkin, J. G.
Right arrow Articles by McElhiney, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rabkin, J. G.
Right arrow Articles by McElhiney, M.
Related Collections
Right arrow Coronary Artery Disease
Right arrow HIV/AIDS
Psychosomatic Medicine 62:413-422 (2000)
© 2000 American Psychosomatic Society


ORIGINAL ARTICLES

Psychological Effects of HAART: A 2-Year Study

Judith G. Rabkin, PhD, Stephen J. Ferrando, MD, Shu-Hsing Lin, PhD, Margaret Sewell, PhD and Martin McElhiney, PhD

From the Department of Psychiatry (J.G.R., S.J.F., M.S., M.M.), Weill College of Medicine, Cornell University, Ithaca; and New York State Psychiatric Institute (J.G.R., S.-H.L.), New York, NY.

Address reprint requests to: Judith G. Rabkin, PhD, New York State Psychiatric Institute, Unit 51, 1051 Riverside Dr., New York, NY 10032. Email: jgr1{at}Columbia.edu

OBJECTIVE: The objectives of this study were to evaluate the psychological consequences of combination antiretroviral treatment in terms of mood, hope, and life satisfaction in men with symptomatic human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome and to compare those whose health improved with those whose health did not improve.

METHODS: One hundred seventy-three HIV+ gay or bisexual men with symptomatic HIV illness (40% nonwhite) were evaluated semiannually in a university-affiliated research program between July 1995 and December 1997. The primary outcome measures were the Structured Clinical Interview for DSM-IV, Beck Depression Inventory, Endicott Quality of Life Enjoyment and Satisfaction Questionnaire, and Beck Hopelessness Scale.

RESULTS: Psychological distress in this sample was mild to moderate at baseline. During the first 2 years that highly active antiretroviral therapy became widely available, we observed a statistically significant but clinically modest reduction in distress in the sample as a whole, with significant covariates of CD4 cell count, HIV symptoms, and social support in a mixed-effects model. Rates of clinical depression declined. However, this generalized mental health improvement was not related to individual medical improvement of markers of HIV illness progression; those classified as improved were no more likely than those who remained unimproved to report greater declines in measures of distress and hopelessness. Number of self-reported physical symptoms were directly related to distress levels.

CONCLUSIONS: A cohort effect was observed, with overall psychological improvement. Physical symptoms were more strongly related to psychological distress than were laboratory markers. Consequently, those whose CD4 cell count and HIV RNA viral load reflected successful treatment were no more likely than others to be relieved of the psychological burdens of illness.

Key Words: psychiatry • psychosocial • highly active antiretroviral therapy • naturalhistory • quality of life

Abbreviations: AIDS = acquired immune deficiency syndrome; BDI = BeckDepression Inventory; BHS = Beck Hopelessness Scale; CD4 =subset of lymphocytes used as a marker of immunosuppression in HIVdisease; DSM-IV = Diagnostic and Statistical Manual ofMental Disorders, fourth edition; HAART = highly activeantiretroviral therapy; HAM-D = Hamilton Rating Scale forDepression; HIV = human immunodeficiency virus; HIV RNA = HIVribonucleic acid; the assay measures number of copies of virus per unitof blood (plasma); QOL = Endicott Quality of Life Enjoyment andSatisfaction Questionnaire; SCID = Structured Clinical Interviewfor DSM-IV.




This article has been cited by other articles:


Home page
Psychosom. Med.Home page
M. J. Repetto and J. M. Petitto
Psychopharmacology in HIV-Infected Patients
Psychosom Med, June 1, 2008; 70(5): 585 - 592.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
R. W. Burgoyne and D. H. S. Tan
Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act
J. Antimicrob. Chemother., March 1, 2008; 61(3): 469 - 473.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
M. H. Antoni, A. W. Carrico, R. E. Duran, S. Spitzer, F. Penedo, G. Ironson, M. A. Fletcher, N. Klimas, and N. Schneiderman
Randomized Clinical Trial of Cognitive Behavioral Stress Management on Human Immunodeficiency Virus Viral Load in Gay Men Treated With Highly Active Antiretroviral Therapy
Psychosom Med, January 1, 2006; 68(1): 143 - 151.
[Abstract] [Full Text] [PDF]


Home page
Chronic IllnessHome page
A. W. Carrico, M. H. Antoni, K. E. Weaver, S. C. Lechner, and N. Schneiderman
Cognitive--behavioural stress management with HIV-positive homosexual men: mechanisms of sustained reductions in depressive symptoms
Chronic Illness, September 1, 2005; 1(3): 207 - 215.
[Abstract] [PDF]


Home page
J Health PsycholHome page
P. N. Halkitis, M. T. Shrem, D. D. Zade, and L. Wilton
The Physical, Emotional and Interpersonal Impact of HAART: Exploring the Realities of HIV Seropositive Individuals on Combination Therapy
J Health Psychol, May 1, 2005; 10(3): 345 - 358.
[Abstract] [PDF]


Home page
PediatricsHome page
D. S. Storm, M. G. Boland, S. L. Gortmaker, Y. He, J. Skurnick, L. Howland, J. M. Oleske, and for the Pediatric AIDS Clinical Trials Group Proto
Protease Inhibitor Combination Therapy, Severity of Illness, and Quality of Life Among Children With Perinatally Acquired HIV-1 Infection
Pediatrics, February 1, 2005; 115(2): e173 - e182.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Public HealthHome page
K. Siegel, D. Karus, and L. Dean
Psychosocial Characteristics of New York City HIV-Infected Women Before and After the Advent of HAART
Am J Public Health, July 1, 2004; 94(7): 1127 - 1132.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
J. G. Rabkin, M. McElhiney, S. J. Ferrando, W. Van Gorp, and S. H. Lin
Predictors of Employment of Men With HIV/AIDS: A Longitudinal Study
Psychosom Med, January 1, 2004; 66(1): 72 - 78.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
M. D. Sullivan
Hope and Hopelessness at the End of Life
Am J Geriatr Psychiatry, August 1, 2003; 11(4): 393 - 405.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
M. F. Morrison, J. M. Petitto, T. T. Have, D. R. Gettes, M. S. Chiappini, A. L. Weber, P. Brinker-Spence, R. M. Bauer, S. D. Douglas, and D. L. Evans
Depressive and Anxiety Disorders in Women With HIV Infection
Am J Psychiatry, May 1, 2002; 159(5): 789 - 796.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
A. Scalera and N. Shear
Use and Citation of Beck Depression Inventory to Assess Depression in HIV Infection
Psychosomatics, February 1, 2002; 43(1): 88 - 88.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Psychosomatic Society